Hematology Top 20 This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the 20 most read items in the past 30 days within this specialty in the MedWorm directory.

ASCO: Antibody Boosts Chemo in CLL
CHICAGO (MedPage Today) -- Adding obinutuzumab to standard chemotherapy improves outcomes for older, sicker patients with chronic lymphocytic leukemia, possibly more than adding rituximab, a pivotal trial showed. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 5, 2013 Category: Hematology Source Type: news

ASCO: Novel Drug Gets High Marks in Early Prostate Cancer
CHICAGO (MedPage Today) -- Men with early, high-risk prostate cancer achieved castrate levels of prostate-specific antigen with stable bone mineral density when treated with the anti-androgen enzalutamide, according to a preliminary clinical study. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 6, 2013 Category: Hematology Source Type: news

A novel fibrinogen B beta chain frameshift mutation causes congenital afibrinogenaemia.
We report a patient with afibrinogenaemia who suffered from umbilical cord bleeding and repeated bleeding episodes. His plasma fibrinogen levels could not be detected using the Clauss method and immunological methods. Molecular analyses revealed homozygosity in a novel four bases insertion in codon 40 of FGB exon 2 (g. 2833_2834 ins GTTT), which resulted in a truncated 50-residue polypeptide that contained 11 exceptional abnormal residues. In the transient expression experiments, mutant fibrinogen could be detected at higher level than wild-type fibrinogen in COS-7 cell lysates but not in culture media. These results sugge...
Source: Thrombosis and Haemostasis - June 6, 2013 Category: Hematology Authors: Zhang J, Zhao X, Wang Z, Yu Z, Cao L, Zhang W, Bai X, Ruan C Tags: Thromb Haemost Source Type: research

Anticoagulation beyond direct thrombin and factor Xa inhibitors: indications for targeting the intrinsic pathway?
Abstract Antithrombotic drugs like vitamin K antagonists and heparin have been the gold standard for the treatment and prevention of thromboembolic disease for many years. Unfortunately, there are several disadvantages of these antithrombotic drugs: they are accompanied by serious bleeding problems, it is necessary to monitor the therapeutic window, and there are various interactions with food and other drugs. This has led to the development of new oral anticoagulants, specifically inhibiting either thrombin or factor Xa. In terms of effectiveness, these drugs are comparable to the currently available anticoagulant...
Source: Thrombosis and Haemostasis - June 6, 2013 Category: Hematology Authors: van Montfoort ML, Meijers JC Tags: Thromb Haemost Source Type: research

The effect of monthly ibandronate on bone mineral density and bone turnover markers in patients with haemophilia A and B and increased risk for fracture.
In conclusion, ibandronate significantly improved BMD in lumbar spine and reduced bone resorption in adults with haemophilia at increased risk of fracture. Its effect on hip BMD and bone formation markers was not significant. PMID: 23740140 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - June 6, 2013 Category: Hematology Authors: Anagnostis P, Vyzantiadis TA, Charizopoulou M, Adamidou F, Karras S, Goulis DG, Karagiannis A, Garipidou V, Vakalopoulou S Tags: Thromb Haemost Source Type: research

Autoantigenic targets of B-cell receptors derived from chronic lymphocytic leukemias bind to and induce proliferation of leukemic cells
In conclusion, autoantigens are frequent targets of CLL-BCRs. Their specific binding to and induction of proliferation in the respective leukemic cells provide the most convincing evidence to date for the long-time hypothesized role of autoantigens in the pathogenesis of CLL. (Source: Blood)
Source: Blood - June 6, 2013 Category: Hematology Authors: Zwick, C., Fadle, N., Regitz, E., Kemele, M., Stilgenbauer, S., Buhler, A., Pfreundschuh, M., Preuss, K.-D. Tags: Lymphoid Neoplasia Source Type: research

SF3B1 mutations in chronic lymphocytic leukemia
SF3B1 is a critical component of the splicing machinery, which catalyzes the removal of introns from precursor messenger RNA (mRNA). Next-generation sequencing studies have identified mutations in SF3B1 in chronic lymphocytic leukemia (CLL) at high frequency. In CLL, SF3B1 mutation is associated with more aggressive disease and shorter survival, and recent studies suggest that it can be incorporated into prognostic schema to improve the prediction of disease progression. Mutations in SF3B1 are predominantly subclonal genetic events in CLL, and hence are likely later events in the progression of CLL. Evidence of altered pre...
Source: Blood - June 6, 2013 Category: Hematology Authors: Wan, Y., Wu, C. J. Tags: Lymphoid Neoplasia, Review Articles, Clinical Trials and Observations Source Type: research

Molecular DNA‐based testing for blood group antigens: recipient–donor focus
DNA‐based testing for blood group antigens has become commonplace in a number of clinical situations to improve transfusion therapy for blood transfusion recipients. These include typing for antigens in patients who are multiply transfused to determine which blood group antibodies may be present, typing when the red blood cells (RBCs) are coated with immunoglobulin, and typing for uncommon antigens, especially when no serologic reagent is available. Other clinical applications include resolving ABO typing discrepancies for patients awaiting transplant, or determination of the original type of a bone marrow transplant rec...
Source: ISBT Science Series - June 1, 2013 Category: Hematology Authors: C. M. Westhoff Tags: State of the Art Source Type: research

ASCO: TKI Offers Hope in Small Cell Lung Cancer
CHICAGO (MedPage Today) -- Maintenance therapy with the oral tyrosine kinase inhibitor sunitinib (Sutent) delayed relapse after chemotherapy in patients with extensive small cell lung cancer, a researcher said here. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 5, 2013 Category: Hematology Source Type: news

June 20: Living Well with Myeloma Teleconference - "The Advantages of Good Nutrition"
INTERNATIONAL MYELOMA FOUNDATION presents Living Well with Myeloma Teleconference Series “The Advantages of Good Nutrition” Date: Thursday, June 20, 2013 Time: 4PM Pacific / 5PM Mountain 6PM Central / 7PM Eastern Speaker: Angela Hummel MS, RD, CSO, LDN Duration: 60 minutes (including Q&A) The IMF’s Living Well with Myeloma Teleconference Series is designed to cover all...
Source: International Myeloma Foundation - June 4, 2013 Category: Hematology Source Type: news

Trithorax and polycomb cooperation in MLL fusion acute leukemia.
PMID: 23729722 [PubMed - in process] (Source: Haematologica)
Source: Haematologica - June 1, 2013 Category: Hematology Authors: Méreau H, Schwaller J Tags: Haematologica Source Type: research

The bone disease associated with factor VIII deficiency in mice is secondary to increased bone resorption
Summary Osteopenia and osteoporosis have increasingly become a recognized morbidity of factor VIII (FVIII) deficiency. Recently, we demonstrated that FVIII knockout (KO) mice had significantly decreased bone mass and bone strength despite the fact that they did not have haemarthroses. The aim of this study was to explore the mechanism of bone disease associated with FVIII deficiency. We compared biochemical markers of bone formation and osteoclastogenesis, inflammatory cytokines, as well as static and dynamic histomorphometry of genetically engineered FVIII KO male mice to those of wild‐type (WT) controls. At 20 weeks o...
Source: Haemophilia - June 4, 2013 Category: Hematology Authors: M. Recht, M. S. Liel, R. T. Turner, R. F. Klein, J. A. Taylor Tags: Original Article Source Type: research

Potent cardioprotection from ischemia-reperfusion injury by a 2-domain fusion protein comprising Annexin V and Kunitz protease inhibitor.
CONCLUSIONS: ANV-6L15 dose-dependently reduced infarct size by up to 87%, and decreased plasma levels of cardiac troponin I, TNF-α, and sICAM-1, by up to 97%, 96%, and 66%, respectively, with little impact on the coagulation parameters. ANV-6L15 also ameliorated hemodynamic derangements, attenuated neutrophil infiltration and reduced TUNEL-(+) apoptotic cardiomyocytes. Hirudin was less efficacious even at supra-clinical dose. ANV-6L15 confers exceptionally potent cardioprotection and is a promising drug candidate for prevention of myocardial I-R injury. This article is protected by copyright. All rights reserved. PMID...
Source: Thrombosis and Haemostasis - June 10, 2013 Category: Hematology Authors: Yeh CH, Chen TP, Wang YC, Fang SW, Wun TC Tags: J Thromb Haemost Source Type: research

Targeted therapy for HER2 positive breast cancer
This article reviews the data presented at 2012 American Society of Clinical Oncology and 2012 San Antonio Breast Cancer Symposium regarding progress made in the field of HER2 positive breast cancer and examines the future of HER2 targeted therapy. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - June 3, 2013 Category: Hematology Authors: Jason IncorvatiShilpan ShahYing MuJanice Lu Source Type: research

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma
Lenalidomide has been linked to myelodysplastic syndrome (MDS) after autotransplants for myeloma. Total therapy trials (TT; TT2–/+ thalidomide) and TT3 (TT3a with bortezomib, thalidomide; TT3b with additional lenalidomide) offered the opportunity to examine the contribution of these immune-modulatory agents to MDS-associated cytogenetic abnormalities (MDS-CA) and clinical MDS or acute leukemia ("clinical MDS/AL"). Of 1080 patients with serial cytogenetic studies, MDS-CA occurred in 11% and clinical MDS/AL in 3%. Risk features of MDS-CA included TT3b, age ≥65 years, male gender, levels of β-2-microglobulin >...
Source: Blood - June 6, 2013 Category: Hematology Authors: Usmani, S. Z., Sawyer, J., Rosenthal, A., Cottler-Fox, M., Epstein, J., Yaccoby, S., Sexton, R., Hoering, A., Singh, Z., Heuck, C. J., Waheed, S., Chauhan, N., Johann, D., Abdallah, A.-O., Muzaffar, J., Petty, N., Bailey, C., Crowley, J., van Rhee, F., Ba Tags: Transplantation, Free Research Articles, Myeloid Neoplasia, Lymphoid Neoplasia, Brief Reports Source Type: research

Just‐in‐time rescue plerixafor in combination with chemotherapy and granulocyte‐colony stimulating factor for peripheral blood progenitor cell mobilization
Abstract Plerixafor, a recently approved peripheral blood progenitor cell mobilizing agent, is often added to granulocyte‐colony stimulating factor (G‐CSF) to mobilize peripheral blood progenitor cells in patients with lymphoma or myeloma who cannot mobilize enough CD34+ cells with G‐CSF alone to undergo autologous stem cell transplantation. However, data are lacking regarding the feasibility and efficacy of just‐in‐time plerixafor in combination with chemotherapy and G‐CSF. We reviewed the peripheral blood stem cell collection data of 38 consecutive patients with lymphoma (Hodgkin's and non‐Hodgkin's) and mu...
Source: American Journal of Hematology - June 8, 2013 Category: Hematology Authors: Veronica R. Smith, Uday Popat, Stefan Ciurea, Yago Nieto, Paolo Anderlini, Gabriela Rondon, Amin Alousi, Muzaffar Qazilbash, Partow Kebriaei, Issa Khouri, Marcos de Lima, Richard Champlin, Chitra Hosing Tags: Research Article Source Type: research

Acute pulmonary embolism during warfarin therapy and long-term risk of recurrent fatal pulmonary embolism.
In conclusion, patients presenting with PE during treatment with warfarin have an increased risk of death from recurrent PE. Admission INR appears to have independent long-term prognostic importance in these patients. PMID: 23740364 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - June 6, 2013 Category: Hematology Authors: Moutzouris JP, Ng AC, Chow V, Chung T, Curnow J, Kritharides L Tags: Thromb Haemost Source Type: research

Antibodies against thrombin in dengue patients contain both anti-thrombotic and pro-fibrinolytic activities.
In this study, we demonstrated that antibodies against human thrombin were increased in the sera of Dengue patients but not in that of patients infected with other viruses. To further characterise the properties of these antibodies, affinity-purified anti-thrombin antibodies (ATAs) were collected from Dengue patient sera by thrombin and protein A/L affinity columns. Most of the ATAs belonged to the IgG class and recognized DENV nonstructural protein 1 (NS1). In addition, we found that dengue patient ATAs also cross-reacted with human plasminogen (Plg). Functional studies in vitro indicated that Dengue patient ATAs could in...
Source: Thrombosis and Haemostasis - June 6, 2013 Category: Hematology Authors: Chuang YC, Lin YS, Liu HS, Wang JR, Yeh TM Tags: Thromb Haemost Source Type: research

Pathophysiological role of neutrophils in acute myocardial infarction.
Abstract The pathogenesis of acute myocardial infarction is known to be mediated by systemic, intraplaque and myocardial inflammatory processes. Among different immune cell subsets, compelling evidence now indicates a pivotal role for neutrophils in acute coronary syndromes. Neutrophils infiltrate coronary plaques and the infarcted myocardium and mediate tissue damage by releasing matrix-degrading enzymes and reactive oxygen species. In addition, neutrophils are also involved in post-infarction adverse cardiac remodelling and neointima formation after angioplasty. The promising results obtained in preclinical model...
Source: Thrombosis and Haemostasis - June 6, 2013 Category: Hematology Authors: Carbone F, Nencioni A, Mach F, Vuilleumier N, Montecucco F Tags: Thromb Haemost Source Type: research

Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells indicating protection against cell activation.
Abstract Hyperlipidaemia is a causal factor in the ethiopathogenesis of atherosclerosis. Statins are the cornerstone drug therapy for LDL-cholesterol (LDL-c) lowering, that exert beneficial effects beyond lipid lowering. Circulating microparticles (cMPs), microvesicles released by activated cells into the bloodstream, are markers of vascular and inflammatory cell activation with tentative role in disease progression. However, the role of statins on cMPs seems controversial. We aimed at the evaluation of the effects of lipid-lowering treatment (LLT) on cMP generation in patients in primary prevention of atherosclero...
Source: Thrombosis and Haemostasis - June 6, 2013 Category: Hematology Authors: Suades R, Padró T, Alonso R, Mata P, Badimon L Tags: Thromb Haemost Source Type: research